Drugs / ε-Aminocaproic Acid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02229968 | Oct 2014 → Jan 2028 expected | craniosynostosis | Children's National Research Institute | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01873768 Comparator | Jan 2014 → Dec 2015 | osteoarthritis | Miller Orthopedic Specialists | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ε-aminocaproic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02229968 ↗ |
| Action | Inhibit | “blocks the lysine binding sites on plasminogen, resulting in antifibrinolytic activity through inhibition of plasmin formation” NCT02229968 ↗ |
| Route | Intravenous | “IV loading dose” NCT02229968 ↗ |